Division of Interventional Cardiology, La Paz University Hospital, Madrid, Spain.
Institute for Health Research, La Paz University Hospital, Madrid, Spain.
Tex Heart Inst J. 2024 Nov 5;51(2). doi: 10.14503/THIJ-22-7997.
Transcatheter heart valve embolization is a serious and rare complication of transcatheter aortic valve replacement. Having a strategy for promptly managing transcatheter heart valve embolization is crucial to avoid emergency conversion from transcatheter aortic valve replacement to open-heart surgery. Many cases of transcatheter heart valve embolization occurring with balloon-expandable prostheses such as the SAPIEN 3 (Edwards LifeSciences Corporation) valve and self-expandable prostheses such as the ACURATE neo (Boston Scientific Corporation) valve have been reported in the literature. Here, for the first time (to the authors' knowledge), the case of a Myval (Meril Life Sciences Pvt Ltd) transcatheter heart valve embolization during transcatheter aortic valve replacement, which was treated percutaneously with favorable outcomes, is reported.
经导管心脏瓣膜栓塞是经导管主动脉瓣置换术的一种严重且罕见的并发症。制定及时处理经导管心脏瓣膜栓塞的策略对于避免紧急将经导管主动脉瓣置换术转为开胸手术至关重要。文献中报道了许多使用球囊扩张式假体(如 SAPIEN 3(爱德华生命科学公司)瓣膜)和自扩张式假体(如 ACURATE neo(波士顿科学公司)瓣膜)发生经导管心脏瓣膜栓塞的病例。在此,作者首次(据作者所知)报告了一例在经导管主动脉瓣置换术中发生的 Myval(梅里尔生命科学私人有限公司)经导管心脏瓣膜栓塞的病例,该病例经皮治疗效果良好。